Table 1 Baseline characteristics of the cohort
Participant stratification | Number | Age at CSF (mean (SD)) | Gender (M:F) | CSF total-tau (pg/ml, mean (SD)) | CSF Aβ42 (pg/ml, mean (SD)) | Total-tau to Aβ42 ratio | Disease duration (mean (SD)) | MMSE (mean (SD)) |
|---|---|---|---|---|---|---|---|---|
Control | 19 | 64.2 (6.9) | 10:9 | 327.9 (93.2) | 1012.7 (237.3) | 0.3 (0.1) | N/A | N/A |
AD biomarker group | 18 | 66.4 (5.9) | 11:7 | 984.4 (543.6) | 471.1 (179.0) | 2.5 (2.0) | 3.5 (2.0) | 21.1 (5.2) |
FTD biomarker group | 48 | 64.0 (6.8) | 34:14 | 376.1 (173.3) | 851.2 (246.1) | 0.5 (0.2) | 5.7 (4.1) | 23.9 (7.0) |
Probable TDP-43 pathology | 18 | 62.6 (5.6) | 13:5 | 456.0 (226.0) | 863.4 (222.5) | 0.5 (0.3) | 6.6 (4.9) | 23.3 (6.7) |
Probable tau pathology | 7 | 64.7 (8.9) | 5:2 | 444.4 (146.4) | 894.3 (214.1) | 0.5 (0.2) | 5.5 (3.1) | 21.1 (10.4) |